Demographic characteristics
|
Sex (M/F)
|
31/48
|
29/23
|
17/17
|
−/−/−
|
Age, (mean ± SD)
|
49.3 ± 12.0
|
48.0 ± 11.7
|
50.9 ± 11.3
|
−/−/−
|
Body mass index, (mean ± SD)
|
28.6 ± 6.2
|
29.0 ± 6.0
|
28.8 ± 6.4
|
−/−/−
|
Smokers, N (%)
|
24 (30)
|
12 (23)
|
7 (21)
|
−/−/−
|
Menopause, N (%)
|
21 (27)
|
12 (23)
|
7 (21)
|
−/−/−
|
Previous fracture, N (%)‡
|
4 (5)
|
2 (4)
|
2 (6)
|
−/−/−
|
Disease-specific characteristics
|
Duration of PSO (years), (mean ± SD)
|
18.1 ± 16.1
|
20.2 ± 11.1
|
20.3 ± 16.4
|
−/−/−
|
Duration of PsA (years), (mean ± SD)
|
2.9 ± 5.2
|
7.8 ± 7.4
|
4.6 ± 7.4
|
< 0.001/0.011/0.018
|
MDA, N (%)
|
28 (35)
|
25 (48)
|
22 (65)
|
−/0.004/−
|
DAPSA
|
DAPSA score, (mean ± SD)
|
17.0 ± 11.4
|
12.3 ± 9.6
|
15.8 ± 17.8
|
0.009/−/−
|
Remission, N (%)
|
7 (9)
|
10 (19)
|
6 (18)
|
−/−/−
|
Low activity, N (%)
|
29 (37)
|
25 (48)
|
13 (38)
|
−/−/−
|
Moderate activity, N (%)
|
24 (30)
|
12 (23)
|
9 (27)
|
−/−/−
|
High activity, N (%)
|
12 (15)
|
2 (4)
|
4 (12)
|
0.040/−/−
|
Nail involvement, N (%)
|
20 (25)
|
7 (14)
|
8 (24)
|
−/−/−
|
Scalp involvement, N (%)
|
35 (44)
|
8 (15)
|
8 (24)
|
0.002/−/−
|
PASI (units), (mean ± SD)
|
4.0 ± 4.7
|
1.2 ± 2.7
|
2.1 ± 7.9
|
< 0.001/0.001/−
|
DLQI (units), (mean ± SD)
|
7.5 ± 6.5
|
3.2 ± 5.3
|
6.0 ± 5.3
|
0.043/−/−
|
HAQ (units), (mean ± SD)
|
0.6 ± 0.5
|
0.5 ± 0.5
|
0.7 ± 0.8
|
−/−/−
|
Diabetes mellitus, N (%)
|
2 (3)
|
3 (6)
|
2 (6)
|
−/−/−
|
Hypertension, N (%)
|
19 (24)
|
14 (27)
|
5 (15)
|
−/−/−
|
Autoantibody status
|
Positive low-titer ACPA, N (%)*
|
1 (1)
|
0
|
1 (3)
|
−/−/−
|
Positive low-titer RF, N (%)**
|
3 (4)
|
0
|
1 (3)
|
−/−/−
|
Anti-rheumatic and bone treatments
|
Vitamin D supplementation, N (%)
|
10 (13)
|
11 (21)
|
9 (27)
|
−/−/−
|
Bisphosphonates, N (%)
|
0
|
1 (2)
|
0
|
−/−/−
|
Current glucocorticoids, N (%)
|
0
|
6 (12)
|
5 (15)
|
0.002/0.001/−
|
Former glucocorticoids intake, N (%)
|
4 (5)
|
13 (25)
|
5 (15)
|
0.001/−/−
|
Duration of glucocorticoids intake (years), (mean ± SD)
|
1.1 ± 1.0
|
2.8 ± 2.2
|
0.4 ± 0.2
|
−/−/0.034
|